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INDRODUCTION
With a mean treatment cost of $22,000 per case,
sepsis currently accounts for at least $16.7 billion
dollars in healthcare expenditures each year. 1  Despite
significant advances in the understanding of sepsis
pathophysiology and in novel therapeutic approaches,
the mortality rate from severe sepsis has changed little
over the past 25 years, remaining at approximately
30-50%.  In the United States approximately 215,000
people die from sepsis annually, roughly equaling the
number of deaths from acute myocardial infarction.1
The impact of sepsis is felt not only in the intensive
care units and hospital wards, but also in the
emergency department (ED), as many patients who
develop sepsis receive their diagnosis and initial
treatment in the ED.  Recent major trials have shown
that ED resuscitation and other early critical care
interventions can have a substantial impact on sepsis
mortality.  This article will define sepsis terms, review
pertinent pathophysiology, and provide a
comprehensive update for emergency physicians
regarding the latest treatments for septic patients in
the ED.
SEPSIS TERMINOLOGY
While the term “septic” is often used informally to
describe patients with a broad range of illness severity,
a standardized classification system was created in
1992 by the American College of Chest Physicians
and the Society of Critical Care Medicine with
specific, tiered definitions designed to more accurately
represent the spectrum of sepsis disease.2  The first
category, systemic inflammatory response
syndrome (SIRS), does not require an infectious
etiology and is met when patients demonstrate at least
two of the following criteria:  1) temperature >38°C
or <36°C; 2) heart rate > 90 beats per minute; 3)
respiratory rate > 20 breaths per minute or PaCO2 <
32 mm Hg; and 4) white blood cell (WBC) count >
12K, < 4K, or with > 10% bands.  Given that many
ED patients with mild illnesses may meet these criteria,
SIRS has low specificity and is of limited utility in the
ED diagnosis of critical illness.
The term sepsis is applied when SIRS is accompanied
by a documented or suspected infection, most
commonly pneumonia, urinary tract infection, or skin/
soft-tissue infection.  Severe sepsis refers to sepsis
with evidence of hypotension, organ dysfunction, or
hypoperfusion evidenced by lactic acidosis, oliguria,
or mental status changes.  Severe sepsis becomes
septic shock when hypotension is refractory to
adequate fluid resuscitation, typically defined as a
500cc bolus of intravenous (IV) crystalloid.  As
expected, mortality rises with increasing illness severity,
ranging from a 16% rate in sepsis to 46% in fulminant
septic shock.3
Finally, multiple organ dysfunction syndrome
(MODS) is an often-irreversible final common
pathway in which several organ systems fail, resulting
in conditions such as acute respiratory distress
syndrome (ARDS), acute tubular necrosis (ATN), and
coagulopathies.  A central theme of this discussionPage 10 The California Journal of Emergency Medicine V:1,Jan-Mar 2004
and of the strategies proposed by Rivers and others
is that septic patients do not typically die immediately
in the ED from septic shock, but they instead die
several days into an ICU course as a result of
MODS.4  Although MODS typically takes at least a
day after the onset of septic shock to fully manifest
itself and is therefore less commonly encountered by
emergency physicians, the consideration of aggressive
new resuscitation strategies in the ED can help prevent
its development and thereby substantially reduce
patient mortality.
PATHOPHYSIOLOGY OF SEPSIS
In a healthy physiologic response to tissue injury or
infection, pro- and anti-inflammatory mediators are
released to protect the host from damaging effects of
insults while facilitating tissue healing and repair.  In
sepsis, however, homeostasis between these
competing mediators may be lost, generally tilting the
balance toward excessive inflammation.5  Sepsis can
therefore become an auto-destructive process in
which the normal localized physiologic response to
infection becomes generalized and over-amplified,
injuring not only infected tissues but also organs remote
from the involved site.5  Examples of this induced auto-
injury pattern include pulmonary endothelial injury
(ARDS), renal microvascular and tubular damage
(ATN), and malperfusion from shunting and
myocardial depression (cardiovascular failure).6
Two of the central mediators of sepsis are nitric oxide
(NO) and the cytokine tumor necrosis factor alpha
(TNFα ).  Along with endotoxin released by gram-
negative organisms, these mediators may damage
endothelial walls and cause increased microvascular
permeability, impairing oxygen extraction by increasing
the oxygen diffusion distance.  They also induce
shunting, further decreasing flow to functional tissue
capillary beds and thereby reducing tissue oxygen
exchange.
Inflammatory mediators impact oxygenation on the
cellular level as well.  TNFα , interleukin-1 (IL-1),
and endotoxin synergistically induce cellular damage.
NO further impedes mitochondrial electron transport
and halts oxidative phosphorylation; lactic acidosis
results when damaged cells are thus unable to utilize
oxygen despite adequate tissue perfusion.  These
effects occur in tissues throughout the body, but their
impact is particularly important in the heart.  TNFα ,
IL-1, and NO significantly depress cardiac ejection
fraction, further exacerbating the shock state.  This
sepsis-induced cardiac dysfunction was once believed
to evolve as a late-stage effect due to global hypoxia,
but it is now recognized as beginning early in sepsis
as a result of the actions of these inflammatory
mediators.
By virtue of venous pooling and fluid transudation,
cytokine-mediated effects also contribute to the
relative and absolute hypovolemia found in early stages
of severe sepsis and septic shock.  While septic shock
is traditionally perceived to be a hyperdynamic state
with increased cardiac output, much of this high output
is attributable to tachycardia and low systemic vascular
resistance without true improvement of perfusion.
Furthermore, a hypodynamic state is often present in
late-stage sepsis, with reduced cardiac output resulting
from myocardial depression.5
TREATMENT APPROACH FOR SEVERE SEPSIS AND
SEPTIC SHOCK
Volumes have been written regarding airway
management, vasopressor therapy, and antibiotic
choices in the treatment of sepsis.   While we will
briefly address these topics, our primary focus is on
three newer therapeutic management strategies:  1)
Early goal-directed therapy, 2) Low-dose
corticosteroids, and 3) Recombinant activated protein
C.
As with all resuscitations, attention to airway and
ventilation in the septic patient is paramount.  Standard
indications of the need for endotracheal intubation
should be implemented.  Of note with regard to other
indications for mechanical ventilation, however, is the
fact that systemic oxygen demand can be reduced via
sedation, analgesia, and cooling measures for febrile
patients.  Some authors advocate the use of such a
strategy to reduce oxygen demand in patients with
septic shock.7Page  11 The California Journal of Emergency Medicine V:1,Jan-Mar 2004
MONITORING
Because traditional sphygmomanometers may provide
unreliable data for patients in shock, invasive
hemodynamic monitoring via arterial catheterization
is generally recommended.  Central venous monitoring
may also be useful, but the clinician must recognize
the limitations of interpreting the data in patients with
pneumonia.  Such patients may have spuriously
elevated central venous pressure (CVP)
measurements, reflecting backup pressure from high
pulmonary vascular resistance.  Lactate levels are
extremely helpful in recognizing subclinical shock, and
serial measurements aid in gauging response to therapy.
Other monitors for critically ill patients, such as
esophageal doppler techniques and echocardiography,
may also be useful.8-9
FLUID AND VASOPRESSOR CHOICES
Formerly a topic of considerable debate, the choice
of crystalloid versus colloid in resuscitation has been
clarified in recent years.  Two meta-analyses have
demonstrated improved outcomes with crystalloids,
while others have shown equivalence.10-12  Given that
colloids are much more expensive than crystalloids,
their use cannot be justified in sepsis resuscitation
outside of the indication for patients with spontaneous
bacterial peritonitis.
Patients who are refractory to fluid resuscitation—
manifested by minimal improvements in lactate levels,
continued oliguria, and other perfusion signs—may
benefit from the use of vasopressive agents.  The
“best” pressor in septic shock has also been a
longstanding controversial issue.  A consensus
statement from the Society of Critical Care Medicine
offers no formal guidelines or recommendations, but
does appear to favor the use of norepinephrine.13  At
this time, there is no definitive evidence of the
superiority of one vasopressive agent over another.
Most importantly, regardless of the agent chosen, its
introduction should be treated as a therapeutic trial;
the clinician should measure indices of perfusion before
and after the introduction of the pressor in order to
determine its efficacy.
PATHOGEN IDENTIFICATION AND ANTIBIOTIC
THERAPY
Prompt delivery of appropriate antibiotics is well
established as a critical component of sepsis therapy.
Although generally of low yield and not clearly
demonstrated to impact the outcome of septic
patients, blood cultures drawn prior to the initiation
of antibiotic therapy are nonetheless recommended.
For intubated patients who may be septic due to
pneumonia, consider ED-based non-bronchoscopic
bronchoalveolar lavage performed by respiratory
therapists; a study of an ED patient cohort intubated
for community-acquired pneumonia demonstrated a
significantly higher rate of pathogen identification
compared to standard care, even when instituted after
the first dose of antibiotics.14
EARLY GOAL-DIRECTED THERAPY
In a landmark study, Rivers et al. demonstrated that a
strategy of early goal-directed therapy (EGDT)
decreases the in-hospital mortality of patients who
present to the ED in septic shock.15  “Goal-directed
therapy” refers to the practice of resuscitating patients
to defined hemodynamic endpoints, targeting specific
cardiac preload, afterload, contractility, oxygen
delivery, and oxygen consumption goals.16  These
parameters are assessed via the monitoring of central
venous pressure (CVP), mean arterial pressure
(MAP), and central venous oxygen saturation
(SCVO2), which is used as a surrogate marker for
oxygen delivery and consumption.
The first goal in this approach is to fluid resuscitate
the patient to a CVP of 8-10 mm Hg using IV
crystalloid boluses.  Once that parameter has been
achieved, a MAP of 65-90 mm Hg is targeted using
vasopressors or vasodilators.  Next, an SCVO2 of 70%
is sought utilizing red blood cell transfusions,
dobutamine support, and occasionally sedation and
mechanical ventilation.
As compared to the standard care control patients,
those who underwent six hours of EGDT in the ED
had a 16% reduction of hospital mortality, a mortality
benefit that persisted at the 28- and 60-day endpoints.Page 12 The California Journal of Emergency Medicine V:1,Jan-Mar 2004
Much like the “golden hour” in trauma, this study
supports the idea of an ED “golden six hour” window
for the treatment of patients in septic shock.
Despite such a clear benefit, this strategy has yet to
become widely used in EDs, potentially due to
perceptions of management complexity, concerns
about significantly longer ED stays, or lack of staffing
and resources to apply such a comprehensive
treatment approach.  Similar to the “stroke team”
concept used by some hospitals, development of
“sepsis teams” that can be paged to the ED for the
purpose of implementing EGDT in appropriate patients
may be considered.  Another obstacle to the
application of EGDT may be the limited availability
and expense of SCVO2  catheters.  At the time of printing,
these catheters are only available from a single
manufacturer at a cost of $400 each.17  Though not
proven in trials, the concepts underlying EGDT may
be implemented without these devices.  SCVO2 can
be periodically measured using venous blood samples
from central venous catheters.
THE ROLE OF LOW-DOSE CORTICOSTEROIDS
IN THE ED
Steroid therapy in sepsis promptly fell out of favor in
the 1980s after the publication of several trials and
meta-analyses showing worse outcomes.  In the past
four years however, steroids have re-emerged as an
integral adjunct to be considered in the treatment of
septic shock.  Why the change in recommended
management?  Recent studies have demonstrated that
many septic shock patients have relative adrenal
insufficiency or inadequate cortisol responsiveness to
the shock state, leading to refractory hypotension.
Current steroid therapy in septic shock is directed at
treating this relative adrenal insufficiency using low dose
physiologic steroids (50-100 mg IV hydrocortisone
every six hours and 50 µg PO fludrocortisone per
day) instead of high dose anti-inflammatory steroids
(dexamethasone 6mg/kg or methylprednisolone 30
mg/kg).
In 2002 a prospective double-blind placebo-
controlled trial by Annane et al. demonstrated a
significant mortality benefit of a seven-day course of
low-dose corticosteroids among a large subgroup of
ICU patients in septic shock.18  The number of patients
needed to treat (NNT) in order to save one life at the
28-day mark in this study was an impressively low
seven among the 77% of their sample found to have
relative adrenal insufficiency.  This effect was achieved
without increased serious adverse effects compared
to placebo.  No benefit was demonstrated in those
patients with normal adrenal reserve, as determined
by the cosyntropin stimulation test.
This cosyntropin stimulation test can be easily
undertaken in the ED by drawing a baseline serum
cortisol level, giving an IV bolus of 250 µg of
cosyntropin, and then repeating the serum cortisol level
30 minutes later.  It is important for emergency
physicians to recognize that even a single dose of
etomidate may suppress the cortisol response, thereby
making the interpretation of this test difficult.  Because
cortisol levels may take several days to return at some
facilities, we recommended starting 50 mg IV
hydrocortisone every six hours in appropriate patients.
If the test shows a normal response to the cosyntropin
challenge (> 9 mcg/dL elevation after cosyntropin),
then relative adrenal insufficiency has been ruled out
and steroids should be discontinued.
ACTIVATED PROTEIN C
Advances in the understanding of the inflammatory
pathophysiology of sepsis have inspired the search
for the “magic bullet,” an anti-cytokine or anti-
inflammatory agent to quell this hyper-inflammation.
Unfortunately, despite hundreds of millions of dollars
in drug development expenses, most of the more than
30 trials looking for this bullet failed to show any
treatment benefit.19-20  Examples of once-promising
agents and techniques that failed to show benefit in
randomized trials include anti-cytokine agents such
as anti-TNFα , anti-IL-1, and anti-NO, as well as
anti-endotoxin, anti-oxidants, antithrombin,
plasmapheresis, and IV immunoglobulin.20
Recently however, drotecogin alfa, a recombinant form
of activated protein C (APC), was demonstrated to
decrease mortality in patients with severe sepsis and
significant organ dysfunction; APC was approved byPage  13 The California Journal of Emergency Medicine V:1,Jan-Mar 2004
the FDA in November 2001.  The efficacy of this
agent may arise from its anti-thrombotic, anti-
inflammatory, and pro-fibrinolytic properties.
A randomized double-blind multicenter trial by
Bernard et al. evaluated the use of recombinant APC
in nearly 1700 patients with less than 24 hours of
severe sepsis or septic shock and demonstrated a
relative mortality reduction of 19.4% (absolute
mortality reduction of 6.1%).21  The NNT was
calculated as one life saved for every 16 patients
treated.  Treatment benefit of drotecogin alpha
persisted regardless of patients’ protein C deficiency
status.  Subgroup analyses demonstrated the greatest
benefit in the sickest patients— those whose predicted
mortality exceeded 60% based on a multivariate model
(principally patients with acute physiology and chronic
health evaluation (APACHE) II scores above 25).  It
is unclear whether or not survival benefit extends to
patients with lower APACHE II scores.22
Treatment with APC is not without drawbacks.  APC
is expensive, costing nearly $7,000 per treatment in a
recent pharmaceutical company-sponsored trial.23
Patients treated with APC had more severe bleeding
events compared to patients who received placebo
(3.5% event rate in the study group versus 2% in the
placebo group), resulting in one life-threatening
complication for every 66 patients treated.21  With
the high cost and potential bleeding risk, patient
selection is crucial.  Many institutions, including our
own, have strict use criteria or limit it to prescription
by intensivists.
Of note to emergency physicians, the above-
mentioned study evaluated an ICU-based population,
and the utility of this treatment has not been assessed
in the ED.  As issues related to ED overcrowding
continue to increase patient wait times for available
ICU beds, there may be a potential role for ED-based
administration of this drug in the future.
CONCLUSION
The successful treatment of septic patients starts with
prompt, judicious care in the ED.  Aggressive, goal-
directed resuscitation and early appropriate antibiotics
are the cornerstones of therapy.  Stress dose steroids
and activated protein C for patients in septic shock
should also be considered.
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